PT3095871T - Rato de cadeia leve comum - Google Patents

Rato de cadeia leve comum

Info

Publication number
PT3095871T
PT3095871T PT16178223T PT16178223T PT3095871T PT 3095871 T PT3095871 T PT 3095871T PT 16178223 T PT16178223 T PT 16178223T PT 16178223 T PT16178223 T PT 16178223T PT 3095871 T PT3095871 T PT 3095871T
Authority
PT
Portugal
Prior art keywords
light chain
common light
chain mouse
mouse
common
Prior art date
Application number
PT16178223T
Other languages
English (en)
Portuguese (pt)
Inventor
J Murphy Andrew
Stevens Sean
Macdonald Lynn
R Buckler David
Davis Samuel
Mcwhirter John
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43663643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3095871(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT3095871T publication Critical patent/PT3095871T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT16178223T 2010-02-08 2011-02-08 Rato de cadeia leve comum PT3095871T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30228210P 2010-02-08 2010-02-08

Publications (1)

Publication Number Publication Date
PT3095871T true PT3095871T (pt) 2019-06-12

Family

ID=43663643

Family Applications (4)

Application Number Title Priority Date Filing Date
PT16178223T PT3095871T (pt) 2010-02-08 2011-02-08 Rato de cadeia leve comum
PT121734560T PT2505654T (pt) 2010-02-08 2011-02-08 Rato de cadeia leve comum
PT191572783T PT3540066T (pt) 2010-02-08 2011-02-08 Rato de cadeia leve comum
PT117037994T PT2501817E (pt) 2010-02-08 2011-02-08 Rato de cadeia leve comum

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT121734560T PT2505654T (pt) 2010-02-08 2011-02-08 Rato de cadeia leve comum
PT191572783T PT3540066T (pt) 2010-02-08 2011-02-08 Rato de cadeia leve comum
PT117037994T PT2501817E (pt) 2010-02-08 2011-02-08 Rato de cadeia leve comum

Country Status (30)

Country Link
US (6) US10143186B2 (https=)
EP (5) EP3540066B1 (https=)
JP (9) JP5955781B2 (https=)
KR (5) KR102116296B1 (https=)
CN (2) CN102791866B (https=)
AU (1) AU2011213585B2 (https=)
BR (1) BR112012019887B1 (https=)
CA (1) CA2789154C (https=)
CY (2) CY1118241T1 (https=)
DK (4) DK3540066T3 (https=)
ES (4) ES2728942T3 (https=)
FI (1) FI3540066T3 (https=)
HR (4) HRP20151188T4 (https=)
HU (3) HUE045591T2 (https=)
IL (4) IL321266A (https=)
LT (3) LT3540066T (https=)
ME (2) ME02288B (https=)
MX (4) MX378870B (https=)
MY (1) MY166529A (https=)
NZ (4) NZ719253A (https=)
PL (4) PL3540066T3 (https=)
PT (4) PT3095871T (https=)
RS (4) RS55315B2 (https=)
RU (2) RU2571205C2 (https=)
SG (4) SG10201500821UA (https=)
SI (4) SI3540066T1 (https=)
SM (4) SMT202600080T1 (https=)
TR (1) TR201906650T4 (https=)
WO (1) WO2011097603A1 (https=)
ZA (1) ZA201205944B (https=)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
PE20081216A1 (es) 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
EP2147594B1 (en) * 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
JP5827127B2 (ja) 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK3622815T3 (da) * 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
SMT202600080T1 (it) * 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130185821A1 (en) * 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PT3034608T (pt) * 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
CN103348012B (zh) * 2010-11-27 2016-06-08 朱坚 一种人源化的转基因动物
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
EP2758534B1 (en) * 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
GB2495083A (en) * 2011-09-26 2013-04-03 Kymab Ltd Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates
HUE034044T2 (en) * 2011-09-30 2018-01-29 Dana Farber Cancer Inst Inc Therapeutic peptides
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
SG11201401181YA (en) 2011-10-17 2014-04-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US20140283153A1 (en) 2011-10-28 2014-09-18 Trianni, Inc. Transgenic animals and methods of use
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201605675WA (en) 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
AR090219A1 (es) 2012-03-02 2014-10-29 Regeneron Pharma Anticuerpos humanos frente a toxinas de clostridium difficile
MX353278B (es) * 2012-03-06 2018-01-05 Regeneron Pharma Raton con cadena ligera comun.
EP2825036B1 (en) * 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
AU2015227453B2 (en) * 2012-03-16 2017-05-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
EP3539374A1 (en) * 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US9248181B2 (en) * 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
AU2013259276B2 (en) 2012-05-10 2018-03-22 Bioatla Llc Multi-specific monoclonal antibodies
MX2014014891A (es) * 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
ME03551B (me) 2012-06-12 2020-07-20 Regeneron Pharma Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
CN111484999B (zh) * 2013-02-20 2024-10-25 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
EP3699190B9 (en) * 2013-02-22 2023-10-04 Regeneron Pharmaceuticals, Inc. Murine cell expressing humanized major histocompatibility complex
JP6456350B2 (ja) * 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
EP4545567A3 (en) * 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HK1218550A1 (zh) * 2013-03-13 2017-02-24 Regeneron Pharmaceuticals, Inc. 常見輕鏈小鼠
EP3841876A1 (en) 2013-03-14 2021-06-30 Erasmus University Medical Center Rotterdam Transgenic mouse for antibody production
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
US20150033372A1 (en) * 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
RU2019121863A (ru) 2013-09-18 2019-08-29 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
AU2014330922A1 (en) * 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA3124228C (en) * 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
ES2833230T3 (es) 2014-05-13 2021-06-14 Univ Pennsylvania Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
CA2960569A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-Laroche Ag Fc-region variants with modified fcrn- and protein a-binding properties
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
WO2016097865A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
CA2979702A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
DK3303396T5 (da) 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US9914777B2 (en) 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
LT3394103T (lt) 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
KR20230006929A (ko) 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
ES2985566T3 (es) 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
MX392069B (es) 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
TWI910495B (zh) 2016-05-13 2026-01-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
CN113831407B (zh) 2016-05-20 2024-06-11 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
KR20250175345A (ko) * 2016-06-21 2025-12-16 테네오바이오, 인코포레이티드 Cd3 결합 항체
CN109715663B (zh) 2016-06-28 2022-11-25 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
WO2018037092A1 (en) 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
PE20241349A1 (es) * 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
MX2019004371A (es) 2016-10-13 2019-11-18 Massachusetts Inst Technology Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos.
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CN110382529B (zh) 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
TWI865430B (zh) 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
CA3076632A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
CN111683966B (zh) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US11780907B2 (en) 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
WO2019241216A1 (en) 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
IL279354B1 (en) 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CA3109513A1 (en) 2018-08-23 2020-02-27 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
CN113316590B (zh) 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CA3110377A1 (en) 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. Anti-staphylococcus antibodies and uses thereof
US11453721B2 (en) 2018-12-19 2022-09-27 Regeneran Pharmaceuticals, Inc. Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
MA54540A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
US12467062B2 (en) 2018-12-21 2025-11-11 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
KR20210126641A (ko) 2019-02-12 2021-10-20 리제너론 파아마슈티컬스, 인크. 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
CA3134335A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
WO2020206330A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
MX2021014893A (es) 2019-06-05 2022-03-11 Regeneron Pharma Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
EP3983015A1 (en) 2019-06-11 2022-04-20 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN118526580A (zh) 2019-06-21 2024-08-23 瑞泽恩制药公司 结合psma和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
EP3986934A1 (en) 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
BR112022002067A2 (pt) 2019-08-08 2022-06-14 Regeneron Pharma Formatos de molécula de ligação ao antígeno
US12077603B2 (en) 2019-08-15 2024-09-03 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
IL292353A (en) 2019-10-28 2022-06-01 Regeneron Pharma Anti-haemagglutinin antibodies and methods of using them
US20220409732A1 (en) 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CN114929343B (zh) 2019-12-06 2025-03-18 瑞泽恩制药公司 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20220140802A (ko) 2020-02-11 2022-10-18 리제너론 파아마슈티컬스, 인크. 항-acvr1 항체 및 이의 용도
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
JP7702428B2 (ja) 2020-05-12 2025-07-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｇｌｐ１ｒアンタゴニスト抗体およびその使用方法
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2023529846A (ja) * 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
CA3192204A1 (en) * 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
MX2023003214A (es) 2020-09-18 2023-05-24 Regeneron Pharma Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
CN114524878B (zh) 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CN118511853A (zh) 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
JP2024542823A (ja) 2021-12-06 2024-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
TW202400228A (zh) 2022-02-25 2024-01-01 美商再生元醫藥公司 減輕細胞激素釋放症候群的給藥方案
WO2023183288A2 (en) * 2022-03-22 2023-09-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibodies for targeting the cardiac conduction system
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
US20230416396A1 (en) 2022-05-18 2023-12-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
EP4554977A1 (en) 2022-07-12 2025-05-21 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024092133A1 (en) 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
TW202430641A (zh) 2023-01-18 2024-08-01 美商基利科學股份有限公司 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
EP4665764A1 (en) 2023-02-13 2025-12-24 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
IL325163A (en) 2023-06-16 2026-02-01 Regeneron Pharma CD40 × CD40 dual-specific antigen-binding molecules and their application
CN121568720A (zh) 2023-07-10 2026-02-24 瑞泽恩制药公司 抗人类cacng1抗体-药物缀合物及其用途
WO2025014913A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1xcd28 antibodies and methods of use thereof
CN121666401A (zh) 2023-07-10 2026-03-13 瑞泽恩制药公司 双特异性PD-L1x4-1BB抗体及其使用方法
EP4630457A1 (en) 2023-08-18 2025-10-15 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025199278A2 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
US20260000758A1 (en) 2024-06-28 2026-01-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
US20260014252A1 (en) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof
WO2026019824A1 (en) 2024-07-16 2026-01-22 Gilead Sciences, Inc. Human immunoglobulin common light chain transgene constructs and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026050255A2 (en) 2024-08-27 2026-03-05 Regeneron Pharmaceuticals, Inc. Anti-slc3a2-apis antigen-binding proteins and methods of use thereof

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929167T2 (de) 1988-09-06 2000-11-16 Xoma Corp., Berkeley Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
CA2351200A1 (en) 1989-12-01 1991-06-13 Gene Pharming Europe Bv Production of recombinant polypeptides by bovine species and transgenic methods
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
JPH08509612A (ja) * 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1995017500A1 (en) 1993-12-23 1995-06-29 Abs Global, Inc. Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
AU745334B2 (en) 1997-03-06 2002-03-21 Advanced Cell Technology, Inc. Method of cloning animals
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
RU2221809C2 (ru) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
WO1999025821A1 (en) 1997-11-18 1999-05-27 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
HK1048138B (zh) 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
EP1268832A4 (en) 2000-02-29 2003-04-02 Univ Auburn PRODUCTION OF ANTIBODIES IN TRANSGENIC PLASTIDES
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
BR0112633A (pt) 2000-07-21 2003-09-16 Us Agriculture Método para substituir, translocar e empilhar dna em genomas eucarióticos
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US6961875B2 (en) 2001-03-22 2005-11-01 International Business Machines Corporation Method and apparatus for capturing event traces for debug and analysis
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1578917A4 (en) 2001-07-19 2008-01-23 Perlan Therapeutics Inc MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
PT1652920E (pt) 2001-10-01 2010-11-08 Deutsches Krebsforsch Processo para a produção de bibliotecas de proteínas e para a selecção de proteínas a partir da mesma
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
WO2003061363A2 (en) 2002-01-17 2003-07-31 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
EP1470161A1 (en) 2002-01-18 2004-10-27 Inovio AS Bispecific antibody dna constructs for intramuscular administration
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
ES2524767T3 (es) 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
CN101962408A (zh) 2002-07-12 2011-02-02 杰斐逊·富特 超人源化抗体
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
CL2003002461A1 (es) 2002-11-27 2005-01-07 Dow Chemical Company Agroscien Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
EP1606387A4 (en) 2003-03-04 2008-04-23 Alexion Pharma Inc VECTORS USED TO PRODUCE CONSTANT HYBRID AREAS
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2473596T3 (es) 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
DK1709081T3 (da) 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
CN1560081A (zh) 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
US20080184380A1 (en) 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
WO2007001422A2 (en) * 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
AU2006242854A1 (en) 2005-04-29 2006-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
AU2005331864A1 (en) 2005-05-14 2006-11-23 Fudan University Piggybac as a tool for genetic manipulation and analysis in vertebrates
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US7850965B2 (en) * 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
AU2007219159B8 (en) 2006-01-25 2012-06-28 Roger Kingdon Craig Generation of heavy-chain only antibodies in transgenic animals
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
JP2010501165A (ja) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
EP2583551A1 (en) 2007-03-13 2013-04-24 National Jewish Health Methods for generation of antibodies
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
AU2008337517B2 (en) 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
EP2147594B1 (en) 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
JP5827127B2 (ja) 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CN102427978B (zh) 2009-05-07 2016-01-20 沃尔沃建筑设备公司 工程机械和用于操作工程机械的方法
CA2758356C (en) 2009-05-29 2016-07-26 Morphosys Ag A collection of vh and vl pairs having favourable biophysical properties and methods for its use
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
EP2502993B1 (en) 2009-11-17 2017-07-26 Sanford Applied Biosciences L.L.C. Human artificial chromosome vector
ES2724975T3 (es) 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT202600080T1 (it) * 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
PT3034608T (pt) 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
SG11201401181YA (en) 2011-10-17 2014-04-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
MX353278B (es) 2012-03-06 2018-01-05 Regeneron Pharma Raton con cadena ligera comun.
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
MX2014014891A (es) 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
EP4545567A3 (en) 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HK1218550A1 (zh) 2013-03-13 2017-02-24 Regeneron Pharmaceuticals, Inc. 常見輕鏈小鼠

Also Published As

Publication number Publication date
EP3540066A1 (en) 2019-09-18
AU2011213585B2 (en) 2014-02-06
DK2501817T4 (da) 2021-07-26
SI2505654T1 (sl) 2016-12-30
US10986820B2 (en) 2021-04-27
IL267362B (en) 2022-02-01
TR201906650T4 (tr) 2019-05-21
EP3095871B1 (en) 2019-04-10
JP2019076108A (ja) 2019-05-23
KR20130010110A (ko) 2013-01-25
JP2015171386A (ja) 2015-10-01
PL2505654T3 (pl) 2017-02-28
CA2789154C (en) 2024-06-11
EP4707299A2 (en) 2026-03-11
HRP20151188T1 (hr) 2015-12-04
IL290085A (en) 2022-03-01
CN105010238A (zh) 2015-11-04
JP6960005B2 (ja) 2021-11-05
JP2022001066A (ja) 2022-01-06
JP2020096633A (ja) 2020-06-25
CY1118241T1 (el) 2017-06-28
PL2501817T5 (pl) 2021-08-16
KR101995735B1 (ko) 2019-07-03
HUE029785T2 (en) 2017-04-28
RU2012138431A (ru) 2014-03-20
CN102791866A (zh) 2012-11-21
BR112012019887B1 (pt) 2021-06-08
US20130302836A1 (en) 2013-11-14
LT3095871T (lt) 2019-05-27
ES2603559T5 (es) 2021-02-22
KR102116296B1 (ko) 2020-05-28
JP6215264B2 (ja) 2017-10-18
SI2501817T2 (sl) 2021-09-30
SMT202600080T1 (it) 2026-03-09
PT2501817E (pt) 2015-11-04
NZ631363A (en) 2016-05-27
KR102283195B1 (ko) 2021-07-29
ES2547142T3 (es) 2015-10-02
MY166529A (en) 2018-07-10
CY1121794T1 (el) 2020-07-31
JP7233504B2 (ja) 2023-03-06
EP2501817B1 (en) 2015-08-26
JP2023062142A (ja) 2023-05-02
EP2505654A1 (en) 2012-10-03
IL321266A (en) 2025-08-01
US20210204531A1 (en) 2021-07-08
HRP20161551T1 (hr) 2016-12-30
HK1174358A1 (zh) 2013-06-07
FI3540066T3 (fi) 2026-02-19
SI2505654T2 (sl) 2020-08-31
RU2571205C2 (ru) 2015-12-20
MX378870B (es) 2025-03-11
MX350983B (es) 2017-09-27
EP3540066B1 (en) 2025-12-24
KR20210095730A (ko) 2021-08-02
JP6666483B2 (ja) 2020-03-13
NZ601679A (en) 2014-01-31
US20110195454A1 (en) 2011-08-11
RS67847B1 (sr) 2026-03-31
SMT201600432B (it) 2017-01-10
SMT201500283B (it) 2016-01-08
SI3095871T1 (sl) 2019-06-28
PL3095871T3 (pl) 2019-10-31
DK2501817T3 (en) 2015-12-07
PT3540066T (pt) 2026-02-26
KR20190077630A (ko) 2019-07-03
IL290085B1 (en) 2025-07-01
US20190040123A1 (en) 2019-02-07
ME02646B (me) 2017-06-20
ZA201205944B (en) 2013-06-26
SG10201913463QA (en) 2020-03-30
RS55315B2 (sr) 2020-08-31
BR122014002928A2 (pt) 2015-12-29
LT3540066T (lt) 2026-03-10
DK3540066T3 (da) 2026-02-16
KR102432611B1 (ko) 2022-08-16
CN105010238B (zh) 2018-07-20
RS59001B1 (sr) 2019-08-30
IL221265B (en) 2020-04-30
DK3095871T3 (da) 2019-06-11
CN102791866B (zh) 2015-07-29
EP2505654B1 (en) 2016-08-24
ES2728942T3 (es) 2019-10-29
HRP20161551T4 (hr) 2020-10-02
US20120192300A1 (en) 2012-07-26
ES2603559T3 (es) 2017-02-28
HUE026229T2 (en) 2016-06-28
ES2547142T5 (es) 2021-12-09
RS55315B1 (sr) 2017-03-31
SI3540066T1 (sl) 2026-04-30
EP2505654B2 (en) 2020-05-13
NZ719253A (en) 2022-08-26
JP7538907B2 (ja) 2024-08-22
EP2501817A1 (en) 2012-09-26
KR101829691B1 (ko) 2018-02-19
JP2013518597A (ja) 2013-05-23
HUE045591T2 (hu) 2019-12-30
RS54367B1 (sr) 2016-04-28
AU2011213585A1 (en) 2012-08-30
PL3540066T3 (pl) 2026-04-13
CA2789154A1 (en) 2011-08-11
HK1231505A1 (en) 2017-12-22
JP6470789B2 (ja) 2019-02-13
RU2015147726A3 (https=) 2019-06-25
US20250386809A1 (en) 2025-12-25
SI2501817T1 (sl) 2015-12-31
IL267362A (en) 2019-08-29
EP2501817B2 (en) 2021-04-21
MX2021000286A (es) 2022-06-08
SG10201500821UA (en) 2015-04-29
RS54367B2 (sr) 2021-08-31
WO2011097603A1 (en) 2011-08-11
HRP20260350T1 (hr) 2026-04-24
HRP20191191T1 (hr) 2019-10-04
JP2024156973A (ja) 2024-11-06
KR20180018838A (ko) 2018-02-21
US10143186B2 (en) 2018-12-04
JP5955781B2 (ja) 2016-07-20
DK2505654T4 (da) 2020-07-27
HRP20151188T4 (hr) 2021-10-01
RU2015147726A (ru) 2019-01-15
PL2501817T3 (pl) 2016-02-29
IL290085B2 (en) 2025-11-01
PL2505654T5 (pl) 2020-11-30
EP3095871A1 (en) 2016-11-23
SMT201900372T1 (it) 2019-09-09
BR112012019887A2 (pt) 2015-09-15
JP2017140050A (ja) 2017-08-17
LT2505654T (lt) 2016-12-12
SG10201610294RA (en) 2017-02-27
NZ619512A (en) 2014-10-31
ME02288B (me) 2016-02-20
RU2724663C2 (ru) 2020-06-25
SG183149A1 (en) 2012-09-27
KR20200060534A (ko) 2020-05-29
PT2505654T (pt) 2016-11-18
IL221265A0 (en) 2012-10-31
JP2018138047A (ja) 2018-09-06
ES3062826T3 (en) 2026-04-14
MX2012009168A (es) 2012-08-31

Similar Documents

Publication Publication Date Title
PT3095871T (pt) Rato de cadeia leve comum
PT3572517T (pt) Murganhos da cadeia leve universal humanizada
EP2614294A4 (en) LED LIGHTING APPARATUS
EP2597688A4 (en) LIGHT-EMITTING ITEM
DK2792936T3 (da) Belysningsindretning
EP2650593A4 (en) LIGHT SOURCE
EP2600427A4 (en) LIGHT-EMITTING MODULE
SG11201405088QA (en) Common light chain mouse
EP2612829A4 (en) Conveyor chain
CN301146283S (zh) 灯
CN301163304S (zh) 灯
CN301163303S (zh) 灯
FI20100354A0 (fi) Uudelleenkäytettävä LED-lamppu
BRDI7106453S (pt) Configuração aplicada em lâmpada de led
UA22118S (uk) Світильник внутрішнього освітлення